ARTICLE | Finance
Plus: Kyverna lining up a listing next week, and PIPEs for Tectonic, Tyra and Arcus
By Paul Bonanos, Director of Biopharma Intelligence
February 2, 2024 10:14 PM UTC
As investors continue to assess signals in the IPO market from two new pricings, a welcoming environment for follow-ons allowed Vaxcyte to raise $750 million amid preparations for a Phase III vaccine program.
Biomarker-driven neuropsychiatry company Alto Neuroscience Inc. (NYSE:ANRO), which built its case to investors with three Phase IIa readouts last year, priced an upsized offering at the top of its range, raising $128.6 million at $16 per share. It’s the third of four NASDAQ biotech listings thus far in 2023 to exceed expectations, following upsized offerings last week by CG Oncology Inc. (NASDAQ:CGON) and ArriVent BioPharma Inc. (NASDAQ:AVBP)…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651332/public-equity-roundup-alto-fractyl-price-ipos-vaxcyte-raises-750m